ARCHIVES

Velcade Addition Can Improve Graft-Versus-Host Outcomes

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

Obituary: Lawrence Garfinkel, ACS Epidemiologist

January 22, 2010

In Brief: BCDDP “Dramatically” Changed U.S. Medical Practice, Fink Says; *% Not too uch-DeVita

December 15, 1978

“Whatever Happened To…?” ACS Follows Up Five Years Later

August 26, 1977

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

DCT Board Approves Contract Recompetitions Worth 44.8 Million In First Year Awards

November 5, 1982